Vertex Pharmaceuticals Inc. on Sunday released the first pivotal data from trials with its Agenerase amprenavir protease inhibitor, demonstrating efficacy with twice daily dosing at 16 weeks comparable to that of marketed protease inhibitors.

An FDA submission with partner Glaxo Wellcome is planned for later this fall. If approved, Agenerase would be the fifth protease inhibitor to reach the U.S. market.